Iongen Therapeutics Secures Over 100 Million RMB in Pre-A Financing Led by Qiming Venture Partners

NANJING, Jan. XX, 2025 -- Iongen Therapeutics Co., Ltd. ("Iongen Therapeutics"), a biotechnology company developing best-in-class non-opioid pain medicines, announced the successful completion of its Pre-A financing round, raising over 100 million RMB. The round was led by Qiming Venture Partners and joined by Insight Capital and Tsinghua Holdings Ginkgo. The investment will support the company's preclinical and early clinical development of its management portfolio, with a focus on accelerating the development of novel Nav1.8 sodium channel-targeting small-molecule drug.

"Our team has long been dedicated to fundamental research on ion channels," said Professor Lei Xiaoguang, Co-Founder of Iongen Therapeutics. "By positioning Iongen Therapeutics as a specialized ion channel drug development platform, we aim to accelerate the development of novel pain therapies and benefit millions of patients worldwide. We are grateful for the unwavering confidence investors have in our assets and platform, and confident that this round will accelerate a smooth and successful execution of our pipeline."

Dr. Chen Kan, Partner and Co-Lead of Healthcare at Qiming Venture Partners, added, "We are impressed by Iongen Therapeutics' innovative approach and scientific expertise in ion channel-targeted drug development. We believe the company's strong R&D capabilities will lead to breakthrough therapies, bringing hope and relief to the growing global population of patients suffering from pain."

About Iongen Therapeutics

Iongen Therapeutics is a biotechnology company dedicated to developing innovative pain management therapies. Co-founded by Professor Lei Xiaoguang from Peking University and Professor Yang Yong, a clinical expert from the Chinese Academy of Medical Sciences Dermatology Hospital, the company has assembled a research and development team with extensive experience in innovative drug development, primarily focusing on discovering novel analgesics targeting Nav1.8 and Nav1.7 sodium ion channels associated with pain perception.

About Qiming Venture Partners

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.

Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status.

About Insight Capital

Insight Capital is a venture capital firm specializing in early-stage investments in the healthcare sector, founded by partners with extensive experience in healthcare industry investments. The firm currently manages a total fund size of over 2 billion RMB. It has strategically invested in more than 40 innovative medical device and healthcare service companies with significant market potential, many of which have grown into leaders within their respective fields. Insight Capital has also successfully completed several profitable exits. Its investors include top-tier domestic fund-of-funds, healthcare industry entrepreneurs, and seasoned investors. With in-depth industry research, a clear investment logic, and comprehensive post-investment management capabilities, Insight Capital has earned continuous support from its investors and long-term respect from entrepreneurs. Insight Capital is committed to becoming a trusted long-term partner for first-class investors and entrepreneurs.

About Tsinghua Holdings Ginkgo

Tsinghua Holdings Ginkgo is a venture capital fund management institution led by the management team. It was established in 2015, with its headquarters located in Beijing. It also has offices in Guangzhou, Wuhan, Shenzhen and Nantong. Since 1999, the team of Tsinghua Holdings Ginkgo has been engaged in the early-stage technology investment business. Successively, it has been engaged in the investment fund management business under the brands of "Tsinghua Science and Technology Incubator", "TusStar Venture Capital" and "Tsinghua Holdings Ginkgo". It adheres to investing in the early stage, innovation and technology, sticks to value investment, and upholds the concept of "conducting venture capital with an entrepreneurial mindset and growing together with entrepreneurial enterprises". It has been working intensively and creating value in the fields of "IBMS", namely Information Technology (I), Biomedicine (B), Advanced Manufacturing (M) and Science and Technology Service (S). Currently, Tsinghua Holdings Ginkgo is managing 13 funds, with a total management scale exceeding 10 billion yuan, and has cultivated more than 20 IPO projects.